Trials / Completed
CompletedNCT00001996
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the incidence of premature discontinuation of therapy due to toxicity. To compare the efficacy of 566C80 with intravenous (IV) pentamidine for the treatment of mild to moderate PCP in the same population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atovaquone | |
| DRUG | Pentamidine isethionate |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00001996. Inclusion in this directory is not an endorsement.